Concentration Interpretation With Nonlinear Pharmacokinetics

Why dose-normalized concentrations can change

Therapeutic drug monitoring often uses a concentration measured at a specified time, or an exposure measure such as area under the concentration-time curve (AUC), to guide interpretation. With linear pharmacokinetics and otherwise unchanged conditions, doubling the dose is expected to double exposure. A concentration-to-dose ratio can then be useful because it tends to remain stable for a patient under comparable dosing and sampling conditions.

That expectation can fail when absorption or elimination is saturable. With saturable absorption, the fraction of a dose reaching systemic circulation may decline as the dose increases. With saturable elimination, the body’s capacity to remove drug may become limiting, so a modest increase in input can produce a disproportionately large increase in concentration. Consequently, dose-normalized concentrations need not be constant across dose levels.

The interpretation still depends on measuring comparable quantities. A trough should be compared with a trough collected at a similar point in the dosing interval, and an AUC should be compared with an AUC over the same interval. The earlier material on concentration-to-dose ratios, sampling time relative to dosing, and steady-state sampling provides the relevant monitoring context. Nonlinearity does not remove the need to establish when the sample was obtained or whether the dosing conditions were comparable.

Saturable elimination and a rising concentration

A standard model for capacity-limited elimination is Michaelis–Menten elimination. The elimination rate increases with concentration but approaches a maximum rate \(V_{\max}\). In the model, \(C\) is drug concentration and \(K_m\) is the concentration at which the elimination rate is half of \(V_{\max}\).

At concentrations well below \(K_m\), the rate is approximately proportional to concentration. As \(C\) becomes large relative to \(K_m\), the elimination rate approaches \(V_{\max}\) rather than continuing to increase in proportion to concentration. Thus, increasing input requires a progressively larger concentration to support the additional elimination.

For a constant intravenous input rate \(R\), a finite steady-state concentration can be found by setting input equal to elimination. This idealized calculation assumes the input rate is constant, the patient’s \(V_{\max}\) and \(K_m\) do not change, the model describes the relevant elimination pathway, and the system has reached steady state. A finite steady-state concentration exists only when \(R<V_{\max}\).

Why the steady-state relationship becomes steep

The steady-state expression shows directly why linear dose adjustment can fail in this model. As input rate \(R\) approaches \(V_{\max}\) from below, the difference \(V_{\max}-R\) approaches zero. The numerator \(K_mR\) remains positive, so the ratio grows sharply. This is a mathematical consequence of the assumed capacity limit, not a statement that every drug follows this model or that a particular patient’s elimination capacity is known.

The same result can be expressed in terms of the input required to maintain a chosen concentration. Rearranging the steady-state balance gives:

This form makes clear that raising concentration toward very high values requires input rates increasingly close to \(V_{\max}\). The rate cannot exceed \(V_{\max}\) in this idealized model while maintaining a finite steady state.

Saturable absorption can also break proportionality

Nonproportional exposure can arise before drug reaches systemic circulation. If absorption is capacity-limited, or if other dose-dependent processes reduce the fraction absorbed, the bioavailability \(F\) can change with dose. Even if elimination is linear, AUC after a dose is proportional to the amount reaching systemic circulation, not necessarily to the administered dose.

For a drug with linear elimination and unchanged clearance \(CL\), the relationship for a single dose is:

This equation assumes that \(F\) and \(CL\) are meaningfully defined for the comparison and that elimination is linear over the relevant concentration range. If \(F\) changes with dose, the AUC-to-dose ratio changes even though clearance remains constant.

Interpreting concentration-to-dose ratios in practice

A changing concentration-to-dose ratio is a signal to question a simple proportional interpretation, not proof of a specific nonlinear mechanism. First check whether the concentrations represent the same exposure metric and comparable sampling times. Then consider whether steady state was reached and whether the dose, interval, formulation, and route were comparable. A ratio can change because exposure itself is nonlinear, but it can also change when bioavailability or clearance changes for other reasons.

A practical interpretation separates the observation from the explanation. For example, “the measured trough per unit dose is higher at the higher dose” describes the data. “Elimination is saturated” proposes a mechanism that requires supporting evidence. A single pair of concentrations generally cannot identify \(V_{\max}\), \(K_m\), dose-dependent bioavailability, or the cause of a changed ratio.

When nonlinearity is suspected, avoid extrapolating a linear dose adjustment without checking the plausible exposure response. Where an adequate model and data are available, calculate the predicted concentration or exposure under the alternative dose and examine whether the change is reasonable. The model must match the route and dosing conditions; the constant-infusion equations above do not directly predict an oral trough.

Assumptions, diagnostics, and limitations

The examples use deliberately simple models to isolate the consequences of saturability. Their assumptions should be checked before applying their equations to monitoring data:

• Comparable measurements: concentrations are sampled at comparable times relative to dosing, or AUCs cover comparable intervals.
• Comparable dosing conditions: the dose, route, interval, formulation, and adherence history are sufficiently characterized for the comparison.
• Steady state when required: a steady-state equation is used only when the input and relevant pharmacokinetics have been stable long enough for steady state to be a reasonable assumption.
• Appropriate structural model: Michaelis–Menten elimination or dose-dependent bioavailability is a stated modeling assumption, not a diagnosis established by one concentration.
• Stable parameters: the examples assume the model parameters do not change between the compared dose levels.

Possible warning signs include a concentration that rises more than expected after a dose increase, a changing dose-normalized AUC or matched-time concentration across dose levels, or an increase in concentration despite a small increase in input when elimination is near capacity. These patterns warrant checking the measurement and dosing context as well as considering nonlinear pharmacokinetics. They do not, by themselves, distinguish saturable absorption from saturable elimination or other causes.

The main alternative is a linear pharmacokinetic interpretation, in which exposure is proportional to dose under otherwise comparable conditions. That is often a useful approximation over a limited dose range, especially when elimination is far from capacity and bioavailability is stable. It should not be treated as a universal rule. Conversely, a nonlinear model should not be invoked merely because two observations fail to lie on a straight line: differences in sampling time, steady-state status, or other changing conditions can also explain the discrepancy.

Common mistake